JP2009533465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533465A5 JP2009533465A5 JP2009505564A JP2009505564A JP2009533465A5 JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5 JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009505564 A JP2009505564 A JP 2009505564A JP 2009533465 A5 JP2009533465 A5 JP 2009533465A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- dvl
- item
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 229920001184 polypeptide Polymers 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 102000013814 Wnt Human genes 0.000 claims description 6
- 108050003627 Wnt Proteins 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 101150108602 DVL1 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79067306P | 2006-04-10 | 2006-04-10 | |
| US60/790,673 | 2006-04-10 | ||
| PCT/US2007/066267 WO2007121147A2 (en) | 2006-04-10 | 2007-04-09 | Disheveled pdz modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533465A JP2009533465A (ja) | 2009-09-17 |
| JP2009533465A5 true JP2009533465A5 (enExample) | 2010-05-20 |
| JP5290148B2 JP5290148B2 (ja) | 2013-09-18 |
Family
ID=38537937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009505564A Expired - Fee Related JP5290148B2 (ja) | 2006-04-10 | 2007-04-09 | Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7695928B2 (enExample) |
| EP (2) | EP2343551B1 (enExample) |
| JP (1) | JP5290148B2 (enExample) |
| CN (2) | CN103351425B (enExample) |
| AU (1) | AU2007238186B2 (enExample) |
| CA (1) | CA2648322C (enExample) |
| ES (2) | ES2487637T3 (enExample) |
| WO (1) | WO2007121147A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI494319B (zh) * | 2007-02-21 | 2015-08-01 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| KR101278073B1 (ko) * | 2008-08-04 | 2013-06-24 | 연세대학교 산학협력단 | Ｉｄｂｆ의 신규 용도 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| BR112014019741A2 (pt) | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
| GB201220901D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| GB201220891D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating breast cancers |
| TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| US9520180B1 (en) | 2014-03-11 | 2016-12-13 | Hypres, Inc. | System and method for cryogenic hybrid technology computing and memory |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8319174D0 (en) * | 1983-07-15 | 1983-08-17 | Erba Farmitalia | Biologically active heptapeptides |
| GB8430255D0 (en) * | 1984-11-30 | 1985-01-09 | Erba Farmitalia | Biologically active oligopeptides |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| WO1990004788A1 (en) | 1988-10-28 | 1990-05-03 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5688936A (en) * | 1992-06-11 | 1997-11-18 | The Regents Of The University Of California | Vesicle membrane transport proteins |
| JPH08503950A (ja) | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| EP1002529A1 (en) | 1994-09-09 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation containing a metal salt of a peptide |
| SK281571B6 (sk) | 1995-06-07 | 2001-05-10 | Alkermes Controlled Therapeutics, Inc. | Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| WO2000006717A2 (en) | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
| WO2002090544A2 (en) | 2001-05-04 | 2002-11-14 | Hybrigenics | Protein-protein interactions in adipocyte cells (3) |
| WO2003004604A2 (en) * | 2001-07-06 | 2003-01-16 | Genentech, Inc. | Phage displayed pdz domain ligands |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| EP1549144A4 (en) | 2002-10-04 | 2010-01-06 | Univ California | METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE |
| JP2008505183A (ja) * | 2004-07-01 | 2008-02-21 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Ｐｄｚ−ドメイン相互作用阻害小分子 |
-
2007
- 2007-04-09 EP EP11154863.2A patent/EP2343551B1/en not_active Not-in-force
- 2007-04-09 ES ES11154863.2T patent/ES2487637T3/es active Active
- 2007-04-09 US US11/733,146 patent/US7695928B2/en not_active Expired - Fee Related
- 2007-04-09 CN CN201310261484.0A patent/CN103351425B/zh not_active Expired - Fee Related
- 2007-04-09 WO PCT/US2007/066267 patent/WO2007121147A2/en not_active Ceased
- 2007-04-09 AU AU2007238186A patent/AU2007238186B2/en not_active Ceased
- 2007-04-09 ES ES07760350T patent/ES2385261T3/es active Active
- 2007-04-09 CN CN2007800216108A patent/CN101467039B/zh not_active Expired - Fee Related
- 2007-04-09 JP JP2009505564A patent/JP5290148B2/ja not_active Expired - Fee Related
- 2007-04-09 CA CA2648322A patent/CA2648322C/en not_active Expired - Fee Related
- 2007-04-09 EP EP07760350A patent/EP2002259B1/en active Active
-
2010
- 2010-01-29 US US12/696,875 patent/US7977064B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Muttenthaler et al. | Solving the α-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists | |
| AU784845B2 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| JP2025137626A (ja) | 安定化ペプチドによって介在される標的タンパク質の分解 | |
| US8278413B2 (en) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway | |
| EA200800536A1 (ru) | Тканезащитные пептиды и их применения | |
| Sakurai et al. | Use of a retroinverso p53 peptide as an inhibitor of MDM2 | |
| Li et al. | ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression | |
| Hoshijima et al. | Roles of heterotypic CCN2/CTGF–CCN3/NOV and homotypic CCN2–CCN2 interactions in expression of the differentiated phenotype of chondrocytes | |
| AU2025204787A1 (en) | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | |
| Malkar et al. | Modulation of triple-helical stability and subsequent melanoma cellular responses by single-site substitution of fluoroproline derivatives | |
| JP2023546561A (ja) | ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 | |
| CN101583871A (zh) | 基于细胞成像利用hbv衣壳蛋白和表面蛋白的相互作用筛选hbv增殖抑制剂的方法 | |
| JP2010528584A5 (enExample) | ||
| EP2268658A1 (en) | Peptides and aptamers thereof as specific modulators of mutant p53 function | |
| Altieri et al. | Anti-amyloidogenic property of human gastrokine 1 | |
| Zwanziger et al. | First selective agonist of the neuropeptide Y1‐receptor with reduced size | |
| ATE253636T1 (de) | Mit smad wechselwirkende polypeptide und verwendungen davon | |
| Denholt et al. | Identification of novel peptide ligands for the cancer‐specific receptor mutation EFGRvIII using a mixture‐based synthetic combinatorial library | |
| JP2021070652A (ja) | 線維芽細胞増殖因子受容体１結合ペプチド | |
| Roof et al. | Novel peptide ligands of RGS4 from a focused one‐bead, one‐compound library | |
| Bánóczi et al. | Synthesis of cell-penetrating conjugates of calpain activator peptides | |
| Sweeney et al. | Determination of the sequence specificity of XIAP BIR domains by screening a combinatorial peptide library | |
| JP2012512259A (ja) | クプレドキシンにより癌を予防するための組成物および方法 | |
| JP2005503782A5 (enExample) | ||
| Katritzky et al. | Microwave‐assisted solid‐phase peptide synthesis utilizing N‐Fmoc‐protected (α‐aminoacyl) benzotriazoles |